GlassScriptPhysician profile
Thomas Lombardo
NPI 1437120789
$1,039.29
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $42.80 · 2021: $231 · 2022: $178 · 2023: $138 · 2024: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $220.48 | 2021-2023 | Opsumit, Uptravi |
| Medtronic, INC. | $181.66 | 2022-2024 | Endurant Iis, Azure Xt Dr Mri Surescan, Micra |
| Janssen Pharmaceuticals, INC | $157.11 | 2019-2022 | |
| Abiomed | $138.64 | 2021 | |
| Boston Scientific Corporation | $133.63 | 2019-2023 | Resonate El Icd Vr |
| Inspire Medical Systems, INC. | $62.83 | 2023 | Inspire |
| Sanofi-Aventis U.S. LLC | $32.54 | 2020-2021 | |
| Abbott Laboratories | $23.79 | 2024 | Diamondback Peripheral |
| E.R. Squibb & Sons, L.L.C. | $20.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.48 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.01 | 2023 | Jardiance |
| Irhythm Technologies, INC. | $12.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.90 | 2019 | |
| Heartflow, INC. | $10.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lombardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.